Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ANASTASIOS MANESSIS

Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism

NPI
1467615823
CMS profile
339477
Location
NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$89,513.63

315 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 3 of 7; records 101–150 of 315 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ANASTASIOS MANESSIS

NPI 1467615823 · CMS profile ID 339477

Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism

NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 7; records 101–150 of 315 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1467615823?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ANASTASIOS MANESSIS, NPI 1467615823, CMS profile ID 339477. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 7; records 101–150 of 315 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1467615823?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). ANASTASIOS MANESSIS, NPI 1467615823, CMS profile ID 339477. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 7; records 101–150 of 315 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1467615823?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
ANASTASIOS MANESSIS, NPI 1467615823, CMS profile ID 339477, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 7; records 101–150 of 315 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1467615823?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

315 matching records · $89,513.63 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 315 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 315.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Astellas Pharma US Inc $25.3307/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139394097 CMS
Novo Nordisk Inc $938.0007/25/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1097382893 CMS
Xeris Pharmaceuticals, Inc. $14.3707/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144586500 CMS
AstraZeneca Pharmaceuticals LP $26.1007/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105708156 CMS
Novo Nordisk Inc $23.1507/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1097198397 CMS
Novo Nordisk Inc $938.0007/19/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1097795955 CMS
Amgen Inc. $22.0707/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111642594 CMS
Novo Nordisk Inc $938.0007/18/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1097623941 CMS
Novo Nordisk Inc $16.9807/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1096909681 CMS
Novo Nordisk Inc $938.0007/16/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1097050677 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $22.4407/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118021784 CMS
Novo Nordisk Inc $750.0007/12/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1096728992 CMS
ABBVIE INC. $16.5407/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104954478 CMS
Mannkind Corporation $23.0507/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145845849 CMS
Mannkind Corporation $0.8207/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145845851 CMS
Astellas Pharma US Inc $25.3307/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139282478 CMS
Lexicon Pharmaceuticals, Inc. $19.3307/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1081718358 CMS
Abbott Laboratories $17.9507/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125079927 CMS
Abbott Laboratories $22.4507/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125079929 CMS
Chiesi USA, Inc. $21.8507/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151812665 CMS
Lilly USA, LLC $800.0007/01/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136046967 CMS
Amneal Pharmaceuticals LLC $22.4806/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139194266 CMS
Medtronic, Inc. $146.1306/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1119331995 CMS
Novo Nordisk Inc $20.5406/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1097142820 CMS
Bayer Healthcare Pharmaceuticals Inc. $26.5206/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086224268 CMS
Mannkind Corporation $341.2006/26/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145845847 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $5.5006/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118021782 CMS
Mannkind Corporation $123.8006/25/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145845841 CMS
Mannkind Corporation $208.6106/25/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145845843 CMS
Mannkind Corporation $41.7106/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145845845 CMS
Novo Nordisk Inc $24.8606/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1096642841 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $24.6806/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118021792 CMS
Novo Nordisk Inc $41.7606/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1097322014 CMS
Mannkind Corporation $116.4806/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145845837 CMS
Mannkind Corporation $64.2806/22/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145845839 CMS
Antares Pharma, Inc. $21.3906/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1146471925 CMS
Lilly USA, LLC $7.2606/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136046981 CMS
Lilly USA, LLC $25.2906/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136034358 CMS
Xeris Pharmaceuticals, Inc. $21.8806/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144586484 CMS
Lilly USA, LLC $27.6606/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136046983 CMS
Mannkind Corporation $46.7206/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145845835 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $2,200.0006/14/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118021810 CMS
Novo Nordisk Inc $20.3606/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1097803846 CMS
Lilly USA, LLC $24.4806/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136034000 CMS
Senseonics, Incorporated $400.0006/13/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154462961 CMS
Mannkind Corporation $26.1106/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145845831 CMS
Mannkind Corporation $0.4606/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145845833 CMS
Lilly USA, LLC $1,800.0006/11/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135998265 CMS
Lilly USA, LLC $675.0006/11/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136031128 CMS
Lilly USA, LLC $1,800.0006/11/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136038667 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $82,447.47 163
PY2020 $62,658.33 184
PY2021 $61,183.04 291
PY2022 $96,129.69 336
PY2023 $89,959.07 343
PY2024 $89,513.63 315
PY2025 $174,539.78 346

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,054,362.02 73
PY2024 Recipient $87,604.50 3
PY2024 Principal investigator $1,039,814.29 179
PY2023 Recipient $530.01 1
PY2023 Principal investigator $676,213.65 202
PY2022 Recipient $37,008.00 3
PY2022 Principal investigator $388,391.24 124
PY2021 Recipient $131.40 1
PY2021 Principal investigator $166,248.83 194
PY2020 Recipient $372.62 1
PY2020 Principal investigator $152,189.47 144
PY2019 Principal investigator $303,982.40 114

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

73 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $5,520.00 12/31/2025 Non-covered Recipient Entity
NYC RESEARCH INC
A Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and safety of Armour Thyroid compared to synthetic T4 for the treatment of adults with primary hypothyroidism No dispute reported 06/30/2026 1202534851
Principal investigator 1 Senseonics, Incorporated $1,300.00 12/24/2025 Non-covered Recipient Entity
NYC RESEARCH, INC.
Senseonics CTP-0039 No dispute reported 06/30/2026 1249852641
Principal investigator 1 Senseonics, Incorporated $2,000.00 12/24/2025 Non-covered Recipient Entity
NYC RESEARCH, INC.
Senseonics CTP-0039 No dispute reported 06/30/2026 1249852643
Principal investigator 1 Novo Nordisk AS $1,350.00 12/22/2025 Non-covered Recipient Entity
NYC RESEARCH, INC
NN9535-4352 No dispute reported 06/30/2026 1213732062
Principal investigator 1 ABBVIE INC. $12,485.20 12/05/2025 Non-covered Recipient Entity
NYC RESEARCH INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202529246
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $1,669.24 12/02/2025 Non-covered Recipient Entity
NYC Research Inc-Manhattan Clinic
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220998447
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
NYC Research Inc-Manhattan Clinic
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220770731
Principal investigator 1 ABBVIE INC. $18,479.50 11/05/2025 Non-covered Recipient Entity
NYC RESEARCH INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202522415
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $24,660.00 11/05/2025 Non-covered Recipient Entity
NYC Research Inc.
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220815195
Principal investigator 1 Eli Lilly and Company $33,914.00 11/03/2025 Non-covered Recipient Entity
NYC RESEARCH INC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF MUVALAPLIN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE HAD A PRIOR ATHEROSCLEROTIC CARDIOVASCULAR EVENT OR ARE AT RISK FOR A FIRST ATHEROSCLEROTIC CARDIOVASCULAR EVENT – MOVE-LP(A) No dispute reported 06/30/2026 1187890156
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
NYC Research Inc-Manhattan Clinic
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220770729
Principal investigator 1 Novo Nordisk AS $839.00 10/29/2025 Non-covered Recipient Entity
NYC RESEARCH, INC
NN9535-4352 No dispute reported 06/30/2026 1213751697
Principal investigator 1 Novo Nordisk AS $949.50 10/29/2025 Non-covered Recipient Entity
NYC RESEARCH, INC
NN9535-4352 No dispute reported 06/30/2026 1213772810
Principal investigator 1 Boehringer Ingelheim International GmbH $259.74 10/27/2025 Non-covered Recipient Entity
NYC Research Inc-Manhattan Clinic
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220770733
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 10/27/2025 Non-covered Recipient Entity
NYC Research Inc-Manhattan Clinic
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220770735
Principal investigator 1 ABBVIE INC. $20,441.20 10/09/2025 Non-covered Recipient Entity
NYC RESEARCH INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202516267
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
NYC Research Inc-Manhattan Clinic
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220770727
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $6,676.96 09/25/2025 Non-covered Recipient Entity
NYC Research Inc-Manhattan Clinic
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220998445
Principal investigator 1 Novo Nordisk AS $400.00 09/19/2025 Non-covered Recipient Entity
NYC RESEARCH, INC
NN9535-4352 No dispute reported 06/30/2026 1213793990
Principal investigator 1 Eli Lilly and Company $65.00 09/09/2025 Non-covered Recipient Entity
NYC RESEARCH INC
A PHASE 3, MULTICENTER, RANDOMIZED, PARALLEL-DESIGN, OPEN-LABEL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 COMPARED WITH INSULIN DEGLUDEC IN PARTICIPANTS WITH TYPE 2 DIABETES CURRENTLY TREATED WITH BASAL INSULIN (QWINT-3) No dispute reported 06/30/2026 1187887366
Principal investigator 1 ABBVIE INC. $21,603.40 09/04/2025 Non-covered Recipient Entity
NYC RESEARCH INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202508898
Principal investigator 1 Boehringer Ingelheim International GmbH $23.75 09/01/2025 Non-covered Recipient Entity
NYC Research Inc-Manhattan Clinic
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220770719
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 09/01/2025 Non-covered Recipient Entity
NYC Research Inc-Manhattan Clinic
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220770721
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
NYC Research Inc-Manhattan Clinic
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220770723
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 09/01/2025 Non-covered Recipient Entity
NYC Research Inc-Manhattan Clinic
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220770725
Principal investigator 1 Senseonics, Incorporated $1,345.00 08/28/2025 Non-covered Recipient Entity
ADVARRA
Senseonics CTP-0039 No dispute reported 06/30/2026 1249851783
Principal investigator 1 Senseonics, Incorporated $5,000.00 08/14/2025 Non-covered Recipient Entity
NYC RESEARCH, INC.
Senseonics CTP-0039 No dispute reported 06/30/2026 1249852635
Principal investigator 1 Senseonics, Incorporated $1,000.00 08/14/2025 Non-covered Recipient Entity
NYC RESEARCH, INC.
Senseonics CTP-0039 No dispute reported 06/30/2026 1249852637
Principal investigator 1 Senseonics, Incorporated $2,500.00 08/14/2025 Non-covered Recipient Entity
NYC RESEARCH, INC.
Senseonics CTP-0039 No dispute reported 06/30/2026 1249852639
Principal investigator 1 ABBVIE INC. $25,468.30 08/06/2025 Non-covered Recipient Entity
NYC RESEARCH INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202503001
Principal investigator 1 Novo Nordisk AS $400.00 07/18/2025 Non-covered Recipient Entity
NYC RESEARCH, INC
NN9535-4352 No dispute reported 06/30/2026 1213757530
Principal investigator 1 Ascendis Pharma Endocrinology Inc $5,000.00 07/03/2025 Non-covered Recipient Entity
NYC Research, Inc.
EAP of Palopegteriparatide in Patients With Hypoparathyroidism No dispute reported 06/30/2026 1233996171
Principal investigator 1 Ascendis Pharma Endocrinology Inc $2,300.00 07/03/2025 Non-covered Recipient Entity
NYC Research, Inc.
EAP of Palopegteriparatide in Patients With Hypoparathyroidism No dispute reported 06/30/2026 1233996183
Principal investigator 1 Ascendis Pharma Endocrinology Inc $1,786.00 07/03/2025 Non-covered Recipient Entity
NYC Research, Inc.
EAP of Palopegteriparatide in Patients With Hypoparathyroidism No dispute reported 06/30/2026 1233996185
Principal investigator 1 Ascendis Pharma Endocrinology Inc $1,482.00 07/03/2025 Non-covered Recipient Entity
NYC Research, Inc.
EAP of Palopegteriparatide in Patients With Hypoparathyroidism No dispute reported 06/30/2026 1233996197
Principal investigator 1 Ascendis Pharma Endocrinology Inc $480.00 07/03/2025 Non-covered Recipient Entity
NYC Research, Inc.
EAP of Palopegteriparatide in Patients With Hypoparathyroidism No dispute reported 06/30/2026 1233996265
Principal investigator 1 Ascendis Pharma Endocrinology Inc $480.00 07/03/2025 Non-covered Recipient Entity
NYC Research, Inc.
EAP of Palopegteriparatide in Patients With Hypoparathyroidism No dispute reported 06/30/2026 1233996267
Principal investigator 1 Ascendis Pharma Endocrinology Inc $480.00 07/03/2025 Non-covered Recipient Entity
NYC Research, Inc.
EAP of Palopegteriparatide in Patients With Hypoparathyroidism No dispute reported 06/30/2026 1233996269
Principal investigator 1 Ascendis Pharma Endocrinology Inc $480.00 07/03/2025 Non-covered Recipient Entity
NYC Research, Inc.
EAP of Palopegteriparatide in Patients With Hypoparathyroidism No dispute reported 06/30/2026 1233996271
Principal investigator 1 Ascendis Pharma Endocrinology Inc $480.00 07/03/2025 Non-covered Recipient Entity
NYC Research, Inc.
EAP of Palopegteriparatide in Patients With Hypoparathyroidism No dispute reported 06/30/2026 1233996273
Principal investigator 1 ABBVIE INC. $25,265.50 07/02/2025 Non-covered Recipient Entity
NYC RESEARCH INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202494603
Principal investigator 1 Eli Lilly and Company $270,306.00 06/10/2025 Non-covered Recipient Entity
NYC RESEARCH INC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY EVALUATING THE EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY COMPARED TO PLACEBO IN ADULT PARTICIPANTS WITH TYPE 1 DIABETES AND OBESITY OR OVERWEIGHT (SURPASS-T1D-1) No dispute reported 06/30/2026 1187886846
Principal investigator 1 Novo Nordisk AS $2,500.00 06/09/2025 Non-covered Recipient Entity
NYC RESEARCH, INC
NN9535-4352 No dispute reported 06/30/2026 1213777544
Principal investigator 1 ABBVIE INC. $46,961.20 06/03/2025 Non-covered Recipient Entity
NYC RESEARCH INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202487995
Principal investigator 1 Novo Nordisk AS $949.50 05/21/2025 Non-covered Recipient Entity
NYC RESEARCH, INC
NN9535-4352 No dispute reported 06/30/2026 1213771191
Principal investigator 1 Novo Nordisk AS $975.00 05/21/2025 Non-covered Recipient Entity
NYC RESEARCH, INC
NN9535-4352 No dispute reported 06/30/2026 1213801517
Principal investigator 1 ABBVIE INC. $23,688.60 05/07/2025 Non-covered Recipient Entity
NYC RESEARCH INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202483243
Principal investigator 1 Novo Nordisk AS $1,501.20 04/21/2025 Non-covered Recipient Entity
NYC RESEARCH, INC
NN9535-4352 No dispute reported 06/30/2026 1213706428
Principal investigator 1 Novo Nordisk AS $1,789.00 04/21/2025 Non-covered Recipient Entity
NYC RESEARCH, INC
NN9535-4352 No dispute reported 06/30/2026 1213749272
Principal investigator 1 ABBVIE INC. $21,084.70 04/03/2025 Non-covered Recipient Entity
NYC RESEARCH INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202469203
Principal investigator 1 ABBVIE INC. $169.94 04/02/2025 Non-covered Recipient Entity
NYC RESEARCH INC
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202468416
Principal investigator 1 ABBVIE INC. $31,287.10 03/07/2025 Non-covered Recipient Entity
NYC RESEARCH INC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202459347
Principal investigator 1 Ascendis Pharma Endocrinology Inc $602.00 03/05/2025 Non-covered Recipient Entity
NYC Research, Inc.
EAP of Palopegteriparatide in Patients With Hypoparathyroidism No dispute reported 06/30/2026 1233995037
Principal investigator 1 Ascendis Pharma Endocrinology Inc $480.00 03/05/2025 Non-covered Recipient Entity
NYC Research, Inc.
EAP of Palopegteriparatide in Patients With Hypoparathyroidism No dispute reported 06/30/2026 1233995043
Principal investigator 1 Ascendis Pharma Endocrinology Inc $480.00 03/05/2025 Non-covered Recipient Entity
NYC Research, Inc.
EAP of Palopegteriparatide in Patients With Hypoparathyroidism No dispute reported 06/30/2026 1233995045
Principal investigator 1 Ascendis Pharma Endocrinology Inc $342.00 03/05/2025 Non-covered Recipient Entity
NYC Research, Inc.
EAP of Palopegteriparatide in Patients With Hypoparathyroidism No dispute reported 06/30/2026 1233995099
Principal investigator 1 Ascendis Pharma Endocrinology Inc $342.00 03/05/2025 Non-covered Recipient Entity
NYC Research, Inc.
EAP of Palopegteriparatide in Patients With Hypoparathyroidism No dispute reported 06/30/2026 1233995101
Principal investigator 1 Ascendis Pharma Endocrinology Inc $342.00 03/05/2025 Non-covered Recipient Entity
NYC Research, Inc.
EAP of Palopegteriparatide in Patients With Hypoparathyroidism No dispute reported 06/30/2026 1233995103
Principal investigator 1 Ascendis Pharma Endocrinology Inc $342.00 03/05/2025 Non-covered Recipient Entity
NYC Research, Inc.
EAP of Palopegteriparatide in Patients With Hypoparathyroidism No dispute reported 06/30/2026 1233995105
Principal investigator 1 Ascendis Pharma Endocrinology Inc $342.00 03/05/2025 Non-covered Recipient Entity
NYC Research, Inc.
EAP of Palopegteriparatide in Patients With Hypoparathyroidism No dispute reported 06/30/2026 1233995107
Principal investigator 1 Ascendis Pharma Endocrinology Inc $342.00 03/05/2025 Non-covered Recipient Entity
NYC Research, Inc.
EAP of Palopegteriparatide in Patients With Hypoparathyroidism No dispute reported 06/30/2026 1233995109
Principal investigator 1 Novo Nordisk AS $1,239.00 02/21/2025 Non-covered Recipient Entity
NYC RESEARCH, INC
NN9535-4352 No dispute reported 06/30/2026 1213757983
Principal investigator 1 Novo Nordisk AS $949.50 02/21/2025 Non-covered Recipient Entity
NYC RESEARCH, INC
NN9535-4352 No dispute reported 06/30/2026 1213798192
Principal investigator 1 ABBVIE INC. $8,182.20 02/06/2025 Non-covered Recipient Entity
NYC RESEARCH INC
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202448041
Principal investigator 1 Eli Lilly and Company $150.00 01/31/2025 Non-covered Recipient Entity
NYC RESEARCH INC
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187887364
Principal investigator 1 Eli Lilly and Company $5,593.32 01/31/2025 Non-covered Recipient Entity
NYC RESEARCH INC
A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES, MODERATE OR SEVERE RENAL IMPAIRMENT WITH INADEQUATE GLYCEMIC CONTROL ON BASAL INSULIN WITH OR WITHOUT METFORMIN AND/OR SGLT2 INHIBITOR No dispute reported 06/30/2026 1187888450
Principal investigator 1 Novo Nordisk AS $1,200.00 01/31/2025 Non-covered Recipient Entity
NYC RESEARCH, INC
NN9535-4352 No dispute reported 06/30/2026 1213826050
Principal investigator 1 Eli Lilly and Company $538.75 01/29/2025 Non-covered Recipient Entity
NYC RESEARCH INC
A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES (ATTAIN-2) No dispute reported 06/30/2026 1187888840
Principal investigator 1 Eli Lilly and Company $1,497.78 01/27/2025 Non-covered Recipient Entity
NYC RESEARCH INC
A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH SEMAGLUTIDE ONCE WEEKLY IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN WITH OR WITHOUT SGLT2 INHIBITOR (TRANSCEND-T2D-2) No dispute reported 06/30/2026 1187888842
Principal investigator 1 Eli Lilly and Company $60,058.00 01/21/2025 Non-covered Recipient Entity
NYC RESEARCH INC
A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES, MODERATE OR SEVERE RENAL IMPAIRMENT WITH INADEQUATE GLYCEMIC CONTROL ON BASAL INSULIN WITH OR WITHOUT METFORMIN AND/OR SGLT2 INHIBITOR No dispute reported 06/30/2026 1187885100
Principal investigator 1 Eli Lilly and Company $143,152.00 01/21/2025 Non-covered Recipient Entity
NYC RESEARCH INC
A PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH SEMAGLUTIDE ONCE WEEKLY IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN WITH OR WITHOUT SGLT2 INHIBITOR (TRANSCEND-T2D-2) No dispute reported 06/30/2026 1187888570
Principal investigator 1 Eli Lilly and Company $27,143.00 01/21/2025 Non-covered Recipient Entity
NYC RESEARCH INC
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187890152
Principal investigator 1 Eli Lilly and Company $172,765.50 01/07/2025 Non-covered Recipient Entity
NYC RESEARCH INC
A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES (ATTAIN-2) No dispute reported 06/30/2026 1187888448